The effect of corticosteroid use in septic shock on secondary infection frequency, microorganism species, morbidity, and mortality

Duygu Kayar Calili 1 * , Seval Izdes 1, Levent Ozturk 1
More Detail
1 Department of Anesthesiology and Reanimation, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey
* Corresponding Author
J CLIN MED KAZ, Volume 20, Issue 5, pp. 9-16.
OPEN ACCESS 300 Views 144 Downloads
Download Full Text (PDF)


Aim: We aimed to examine the effect of corticosteroid treatment in vasopressor-refractory septic shock on secondary infections, microorganism species, survival, and length of hospital stay.
Material and methods: In this observational study, the records of 108 septic shock patients admitted to the intensive care unit (ICU) were reviewed. Patients were divided into two groups: the corticosteroid group (Group S, n=60) and the non-corticosteroid group (Group S-0, n=48). The results of three cultures [blood, endotracheal aspirate (eta), urine, wound] taken after ICU admission were recorded. The groups were compared in terms of demographic characteristics, culture growth rates and microorganisms, length of hospital stay, and survival rates.
Results: The hospital (p=0.043) and ICU stay (p=0.035) were longer in Group S. There was no significant difference between the groups in terms of survival (p>0.05). The growth rate of the first urine culture was significantly higher in Group S-0 than in Group S (p=0.018), but there was no difference in terms of microorganism species (p>0.05). There was no significant difference in growth rates and microorganism species in blood, eta and wound cultures (p>0.05), but increase in growth rates were observed in the 2nd and 3rd eta and, wound cultures compared to first culture in Group S (p<0.05).
Conclusion: There was no difference between the patients who received and did not receive corticosteroid treatment in septic shock in terms of culture growth rates, growing microorganism species and mortality; however, the frequency of growth in eta and wound cultures increased and the length of hospital stay was longer in patients who received corticosteroids.


Calili DK, Izdes S, Ozturk L. The effect of corticosteroid use in septic shock on secondary infection frequency, microorganism species, morbidity, and mortality. J CLIN MED KAZ. 2023;20(5):9-16.


  • Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018;392(10141):75-87.
  • Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247.
  • Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y, et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst Rev. 2019;12(12):CD002243.
  • Cohen R. Use of corticosteroids in septic shock. Minerva Anestesiol. 2011;77(2):190-5.
  • Ramanan M, Cohen J, Venkatesh B. Steroids and Sepsis: The Debate Continues. Int Anesthesiol Clin. 2019;57(2):17-30.
  • Williams DM. Clinical Pharmacology of Corticosteroids. Respir Care. 2018;63(6):655-670.
  • Gibbison B, López-López JA, Higgins JP, Miller T, Angelini GD, Lightman SL, et al. Corticosteroids in septic shock: a systematic review and network meta- analysis. Crit Care. 2017;21(1):78.
  • Robertson JO, Criss CN, Hsieh LB, Matsuko N, Gish JS, Mon RA, et al. Steroid use for refractory hypotension in congenital diaphragmatic hernia. Pediatr Surg Int. 2017; 33(9):981-987.
  • Rochwerg B, Oczkowski SJ, Siemieniuk RAC, Agoritsas T, Belley-Cote E, D'Aragon F, et al. Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis. Crit Care Med. 2018; 46(9):1411-1420.
  • Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45(3):486-552.
  • Hodgens A, Sharman T. Corticosteroids. In: Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2021. PMID:32119499
  • Iqbal N, Irfan M, Siddiqui F, Arshad V, Zuabairi ABS. Effects of systemic steroids on patients with community-acquired pneumonia: Observational study from a tertiary care hospital of a developing country. Respir Investig. 2020;58(6):495-501.
  • Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2017; 12(12):CD007720.
  • Tongyoo S, Permpikul C, Mongkolpun W, Vattanavanit V, Udompanturak S, Kocak M, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016;20(1):329.
  • Wen Y, Zhu Y, Jiang Q, Guo N, Cai Y, Shen X. The Effectiveness and Safety of Corticosteroids Therapy in Adult Critical Ill Patients with Septic Shock: A Meta-Analysis of Randomized Controlled Trials. Shock. 2019; 52(2):198-207.
  • Fang F, Zhang Y, Tang J, Lunsford LD, Li T, Tang R, et al. Association of Corticosteroid Treatment with Outcomes in Adult Patients with Sepsis: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019;179(2):213-223.
  • Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S; CRICS-TRIGGERSEP Network. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018;378(9):809-818.
  • Schäfer ST, Gessner S, Scherag A, Rump K, Frey UH, Siffert W, et al. Hydrocortisone fails to abolish NF-κB1 protein nuclear translocation in deletion allele carriers of the NFKB1 promoter polymorphism (-94ins/delATTG) and is associated with increased 30-day mortality in septic shock. PLoS One. 2014; 9(8):e104953.
  • Nazer L, AlNajjar T, Al-Shaer M, Rimawi D, Hawari F. Evaluating the effectiveness and safety of hydrocortisone therapy in cancer patients with septic shock. J Oncol Pharm Pract. 2015;21(4):274-9.
  • Chaudhary NS, Donnelly JP, Moore JX, Baddley JW, Safford MM, Wang HE. Association of baseline steroid use with long-term rates of infection and sepsis in the REGARDS cohort. Crit Care. 2017;21(1):185.
  • Ruiz-Ruigómez M, Dueñas C, Hernandez C, Vinuesa D, Coronado-Álvarez NM, Portillo-Tuñón V, et al. Clinical predictors of candidemia in medical non-neutropenic, non-ICU patients. The CaMed score. Int J Clin Pract. 2018; 72(12): e13275.
  • Gomila A, Carratalà J, Eliakim-Raz N, Shaw E, Wiegand I, Vallejo-Torres L, et al. Risk factors and prognosis of complicate urinary tract infections caused by Pseudomonas aeruginosa in hospitalized patients: a retrospective multicenter cohort study. Infect Drug Resist. 2018; 11:2571-2581.
  • Santella B, Folliero V, Pirofalo GM, Serretiello E, Zannella C, Moccia G, et al. Sepsis-A Retrospective Cohort Study of Bloodstream Infections. Antibiotics. 2020; 9(12):851.
  • Selby LM, Rupp ME, Cawcutt KA. Prevention of Central-Line Associated Bloodstream Infections: 2021 Update. Infect Dis Clin North Am. 2021; 35(4):841-856.
  • García H, Torres-Gutiérrez J, Peregrino-Bejarano L, Cruz-Castañeda MA. Risk factors for nosocomial infection in a level III Neonatal Intensive Care Unit [Factores de riesgo asociados a infección nosocomial (IN) en una Unidad de Cuidados Intensivos Neonatales (UCIN) de tercer nivel]. Gac Med Mex. 2015;151(6):711-9.
  • Bolat F, Uslu S, Bolat G, Comert S, Can E, Bulbul A, et al. Healthcare- associated infections in a Neonatal Intensive Care Unit in Turkey. Indian Pediatr. 2012; 49(12):951-7.
  • Ballouz T, Aridi J, Afif C, Irani J, Lakis C, Nasreddine R, et al. Risk Factors, Clinical Presentation, and Outcome of Acinetobacter baumannii Bacteremia. Front Cell Infect Microbiol. 2017; 7:156.
  • Tofas P, Samarkos M, Piperaki ET, Kosmidis C, Triantafyllopoulou ID, Kotsopoulou M, et al. Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatmenttreatment, and outcome. Diagn Microbiol Infect Dis. 2017;88(4):335-341.
  • Keighley CL, Pope A, Marriott DJE, Chapman B, Bak N, Daveson K, et al. Risk factors for candidemia: A prospective multi-center case-control study. Mycoses. 2021; 64(3):257-263.
  • Thompson GR 3rd, Young JH. Aspergillus Infections. N Engl J Med. 2021; 385(16):1496-1509.
  • Kourbeti IS, Vakis AF, Ziakas P, Karabetsos D, Potolidis E, Christou S, et al. Infections in patients undergoing craniotomy: risk factors associated with post-craniotomy meningitis. J Neurosurg. 2015; 122(5):1113-9.
  • Russo A, Giuliano S, Ceccarelli G, Alessandri F, Giordano A, Brunetti G, et al. Comparison of Septic Shock Due to Multidrug-Resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit Patients. Antimicrob Agents Chemother. 2018; 62(6):e02562-17.
  • Kofteridis DP, Andrianaki AM, Maraki S, Mathioudaki A, Plataki M, Alexopoulou C, et al. Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2020; 39(5):965-970.
  • But A, Yetkin MA, Kanyilmaz D, Aslaner H, Baştuğ A, Aypak A, et al. Analysis of epidemiology and risk factors for mortality in ventilator-associated pneumonia attacks in intensive care unit patients. Turk J Med Sci. 2017; 47(3):812-816.
  • Liu P, Li X, Luo M, Xu X, Su K, Chen S, et al. Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Infection: A Meta-Analysis. Microb Drug Resist. 2018; 24(2):190-198.
  • Jabbour JF, Kanj SS. Gram-Negative Skin and Soft Tissue Infections. Infect Dis Clin North Am. 2021; 35(1):157-167.